INCY - CTI BioPharma slips after disclosing data for myelofibrosis therapy

CTI BioPharma (NASDAQ:CTIC), a commercial-stage biotech focused on blood-related cancers, dropped ~9% in the pre-market Friday after the company disclosed data for its FDA-approved therapy pacritinib from patients with myelofibrosis and thrombocytopenia. The data from Phase 3 PERSIST-2 and Phase 2 PAC203 studies are part of two presentations scheduled for today at the European Hematology Association (EHA) 2022 Congress. One presentation included data from the Phase 3 PERSIST-2 trial, which was designed to evaluate pacritinib versus ruxolitinib, sold by Incyte (INCY) under the brand name Jakafi. The analysis indicated a similar incidence of bleeding events as well as overall and fatal adverse events for pacritinib and ruxolitinib. Notably, the cardiac events were more common in patients who received pacritinib, CTI (CTIC) said, attributing the difference mainly to higher rates of grade 1 peripheral edema on the therapy. The second presentation comprising data from Phase 3 PERSIST-2 and Phase 2 PAC203 studies showed

For further details see:

CTI BioPharma slips after disclosing data for myelofibrosis therapy